Back to Search Results
Back to Results
Gynecologic
General Information
Study Name:
A randomized Phase II study of chemoradiation and pembrolizumab for locally advanced cervical cancer
Age Group:
Adult
Protocol Number:
NCT02635360
Background Information:
The purpose of this study is to evaluate the safety and effectiveness of immunotherapy in combination with chemotherapy and radiation (chemoradiation) for the treatment of advanced cervical cancer. Pembrolizumab, a type of immunotherapy called a checkpoint inhibitor, will be administered after or during chemoradiation.
Offered at:
3289 Woodburn Rd Suite 320
Annandale, VA 22003
Eligibility Information
Confirmed cervical cancer.
Must have adequate organ function.
Ineligibility Information
Subject is pregnant.
Recurrent cervical cancer.
Distant metastases.
Malignancy within the last 5 years; basal cell carcinoma or squamous cell carcinoma of the skin that has undergone potentially curative therapy is permissable.
Subject has had prior radiation, chemotherapy, targeted therapy, or investigational therapy for cervical cancer.
Subject has a immunodeficiency.
Known history of HIV, Hepatitis B, Hepatitis C, TB, or inflammatory bowel disease.
Hypersensitivity to pembrolizumab or similar drugs.
Subject has an active autoimmune disease in the past 2 years.
Known history of non-infectious pneumonitis.
Subject has an active infection.
Subject has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases are permissible. Talk to Study Contact for specifics.
Contact Information
Contact Name:
Stacey Banks, BA, CCRC
Contact Phone:
703-970-6553
Contact Email:
stacey.banks@inova.org
Additional information can be found at
https://clinicaltrials.gov/ct2/show/study/NCT02635360